Adverse events in bevacizumab and chemotherapy: patient management.

2.50
Hdl Handle:
http://hdl.handle.net/10541/69598
Title:
Adverse events in bevacizumab and chemotherapy: patient management.
Authors:
Blowers, Elaine; Hall, Kate
Abstract:
Bevacizumab (Avastin) is an anti-angiogenic agent recently approved for the treatment of metastatic breast cancer in combination with paclitaxel. It is important that nurses are familiar with the side-effects associated with this agent--several of which differ from those seen with traditional chemotherapy agents--and how these can be optimally identified, monitored and managed. Side-effects associated with bevacizumab include hypertension, proteinuria, thromboembolic events, bleeding, cardiac toxicity, wound-healing complications and gastrointestinal perforations. Many of these are easily manageable, often without the need to discontinue bevacizumab therapy. This article, the second in a series, provides nurses with management recommendations for these toxicities in order to deliver optimal patient care and improve patients quality of life.
Affiliation:
Christie Hospital NHS Foundation Trust, Manchester.
Citation:
Adverse events in bevacizumab and chemotherapy: patient management., 18 (7):424-8 Br J Nurs
Journal:
British Journal of Nursing
Issue Date:
Feb-2009
URI:
http://hdl.handle.net/10541/69598
PubMed ID:
19373187
Type:
Article
Language:
en
ISSN:
0966-0461
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorBlowers, Elaine-
dc.contributor.authorHall, Kate-
dc.date.accessioned2009-06-02T14:05:00Z-
dc.date.available2009-06-02T14:05:00Z-
dc.date.issued2009-02-
dc.identifier.citationAdverse events in bevacizumab and chemotherapy: patient management., 18 (7):424-8 Br J Nursen
dc.identifier.issn0966-0461-
dc.identifier.pmid19373187-
dc.identifier.urihttp://hdl.handle.net/10541/69598-
dc.description.abstractBevacizumab (Avastin) is an anti-angiogenic agent recently approved for the treatment of metastatic breast cancer in combination with paclitaxel. It is important that nurses are familiar with the side-effects associated with this agent--several of which differ from those seen with traditional chemotherapy agents--and how these can be optimally identified, monitored and managed. Side-effects associated with bevacizumab include hypertension, proteinuria, thromboembolic events, bleeding, cardiac toxicity, wound-healing complications and gastrointestinal perforations. Many of these are easily manageable, often without the need to discontinue bevacizumab therapy. This article, the second in a series, provides nurses with management recommendations for these toxicities in order to deliver optimal patient care and improve patients quality of life.en
dc.language.isoenen
dc.subjectBevacizumaben
dc.subjectBreast Canceren
dc.subjectChemotherapyen
dc.subjectNurse Educationen
dc.subjectSide Effectsen
dc.titleAdverse events in bevacizumab and chemotherapy: patient management.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Foundation Trust, Manchester.en
dc.identifier.journalBritish Journal of Nursingen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.